• Policy
    • FAQ JLUdocs
    • FAQ JLUdata
    • Publishing in JLUdocs
    • Publishing in JLUdata
    • Publishing Contract
    • English
    • Deutsch
View Item 
  •   JLUpub Home
  • JLUdocs
  • Publikationen im Open Access gefördert durch die UB
  • View Item
  •   JLUpub Home
  • JLUdocs
  • Publikationen im Open Access gefördert durch die UB
  • View Item
  • Info
    • Policy
    • FAQ JLUdocs
    • FAQ JLUdata
    • Publishing in JLUdocs
    • Publishing in JLUdata
    • Publishing Contract
  • English 
    • English
    • Deutsch
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease - In Vitro Studies in Intestinal Cells and Duodenal Biopsies

Thumbnail
Files in this item
10.3390_ijms24054795.pdf (2.411Mb)
Date
2023
Author
Stricker, Sebastian
de Laffolie, Jan
Zimmer, Klaus-Peter
Rudloff, Silvia
Metadata
Show full item record
BibTeX Export
Quotable link
http://dx.doi.org/10.22029/jlupub-15612
Abstract

Enzymatic modification of gliadin peptides by human transglutaminase 2 (TG2) is a key mechanism in the pathogenesis of celiac disease (CD) and represents a potential therapeutic target. Recently, we have identified the small oxidative molecule PX-12 as an effective inhibitor of TG2 in vitro. In this study, we further investigated the effect of ... PX-12 and the established active-site directed inhibitor ERW1041 on TG2 activity and epithelial transport of gliadin peptides. We analyzed TG2 activity using immobilized TG2, Caco-2 cell lysates, confluent Caco-2 cell monolayers and duodenal biopsies from CD patients. TG2-mediated cross-linking of pepsin-/trypsin-digested gliadin (PTG) and 5BP (5-biotinamidopentylamine) was quantified by colorimetry, fluorometry and confocal microscopy. Cell viability was tested with a resazurin-based fluorometric assay. Epithelial transport of promofluor-conjugated gliadin peptides P31-43 and P56-88 was analyzed by fluorometry and confocal microscopy. PX-12 reduced TG2-mediated cross-linking of PTG and was significantly more effective than ERW1041 (10 µM, 15 ± 3 vs. 48 ± 8%, p < 0.001). In addition, PX-12 inhibited TG2 in cell lysates obtained from Caco-2 cells more than ERW1041 (10 µM; 12 ± 7% vs. 45 ± 19%, p < 0.05). Both substances inhibited TG2 comparably in the intestinal lamina propria of duodenal biopsies (100 µM, 25 ± 13% vs. 22 ± 11%). However, PX-12 did not inhibit TG2 in confluent Caco-2 cells, whereas ERW1041 showed a dose-dependent effect. Similarly, epithelial transport of P56-88 was inhibited by ERW1041, but not by PX-12. Cell viability was not negatively affected by either substance at concentrations up to 100 µM. PX-12 did not reduce TG2 activity or gliadin peptide transport in confluent Caco-2 cells. This could be caused by rapid inactivation or degradation of the substance in the Caco-2 cell culture. Still, our in vitro data underline the potential of the oxidative inhibition of TG2. The fact that the TG2-specific inhibitor ERW1041 reduced the epithelial uptake of P56-88 in Caco-2 cells further strengthens the therapeutic potential of TG2 inhibitors in CD.

Original publication in

International journal of molecular sciences 24 (2023), 1-14, 4795

URI of original publication
https://doi.org/10.3390/ijms24054795
Collections
  • Publikationen im Open Access gefördert durch die UB
Namensnennung 4.0 International
Namensnennung 4.0 International

Contact Us | Impressum | Privacy Policy | OAI-PMH
 

 

Browse

All of JLUpubCommunities & CollectionsOrganisational UnitDDC-ClassificationPublication TypeAuthorsBy Issue DateThis CollectionOrganisational UnitDDC-ClassificationPublication TypeAuthorsBy Issue Date

My Account

LoginRegister

Statistics

View Usage Statistics

Contact Us | Impressum | Privacy Policy | OAI-PMH